News

Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer
Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...
River Journal Online10h
Regeneron Outbid in Effort to Acquire 23andMe
Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...
BioPharma Dive15h
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
Pharmaceutical Technology1d
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
Lynozyfic’s global sales are projected to reach $707 million by 2031.
Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million
Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...
Founder of 23andMe buys back company out of bankruptcy auction
TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...
23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as expected in the third quarter of this year.
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...